Found: 39
Select item for more details and to access through your institution.
Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐on‐Chronic Liver Failure. Authors' Reply.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Correction to 'A Personalised Algorithm Predicting the Risk of Intravenous Corticosteroid Failure in Acute Ulcerative Colitis'.
- Published in:
- 2024
- Publication type:
- Correction Notice
Letter: Filling the Gaps—Enhancing MASLD Prognosis With Imaging, Diverse Populations and Extended Follow‐Up. Authors' Reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1664, doi. 10.1111/apt.18356
- By:
- Publication type:
- Article
Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1656, doi. 10.1111/apt.18352
- By:
- Publication type:
- Article
Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease—Author's Reply.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1660, doi. 10.1111/apt.18348
- By:
- Publication type:
- Article
Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE? Authors' Reply.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Letter: Hepatoprotective Effects of Medications Used in Diabetes Mellitus—Optimal Glycaemic Control Is Just the Tip of the Iceberg.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1666, doi. 10.1111/apt.18342
- By:
- Publication type:
- Article
Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poorer Prognosis in Patients With Non‐HBV‐Related HCC—Authors' Reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1647, doi. 10.1111/apt.18340
- By:
- Publication type:
- Article
Letter: Filling the Gaps—Enhancing MASLD Prognosis With Imaging, Diverse Populations and Extended Follow‐Up.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1662, doi. 10.1111/apt.18338
- By:
- Publication type:
- Article
Letter: Metabolic Dysfunction‐Associated Steatotic Liver Disease in Primary Biliary Cholangitis—Friend, Foe or Red Herring? Authors' Reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1643, doi. 10.1111/apt.18332
- By:
- Publication type:
- Article
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1525, doi. 10.1111/apt.18331
- By:
- Publication type:
- Article
Letter: Association of Myokines With Disease Progression and Outcomes in Patients With Alcohol‐Associated Liver Disease—Authors' Reply'.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1639, doi. 10.1111/apt.18329
- By:
- Publication type:
- Article
Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1658, doi. 10.1111/apt.18327
- By:
- Publication type:
- Article
Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1512, doi. 10.1111/apt.18326
- By:
- Publication type:
- Article
Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1652, doi. 10.1111/apt.18317
- By:
- Publication type:
- Article
Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1654, doi. 10.1111/apt.18307
- By:
- Publication type:
- Article
Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Letter: Metabolic Dysfunction–Associated Steatotic Liver Disease in Primary Biliary Cholangitis—Friend, Foe or Red Herring?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1641, doi. 10.1111/apt.18302
- By:
- Publication type:
- Article
Editorial: Prediction in Inflammatory Bowel Disease—Do the Answers Lie in Big Clinical Data?
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Editorial: To Stop Or Not To Stop: Is It Still A Question?
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Letter: Assessing the prognostic value of agile 3+ and agile 4 scores in predicting chronic kidney disease development in patients with metabolic dysfunction‐associated steatotic liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1633, doi. 10.1111/apt.18287
- By:
- Publication type:
- Article
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1599, doi. 10.1111/apt.18286
- By:
- Publication type:
- Article
Letter: Reflections on the significance of myokines in alcohol‐associated liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1635, doi. 10.1111/apt.18285
- By:
- Publication type:
- Article
Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1631, doi. 10.1111/apt.18282
- By:
- Publication type:
- Article
The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction‐associated steatotic liver disease and metabolic dysfunction and alcohol‐associated liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1587, doi. 10.1111/apt.18280
- By:
- Publication type:
- Article
Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1573, doi. 10.1111/apt.18278
- By:
- Publication type:
- Article
Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1561, doi. 10.1111/apt.18276
- By:
- Publication type:
- Article
A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1549, doi. 10.1111/apt.18275
- By:
- Publication type:
- Article
Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1534, doi. 10.1111/apt.18274
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 11/12, p. 1509, doi. 10.1111/apt.17625
- Publication type:
- Article